Clo­vis spikes ovar­i­an can­cer com­bo af­ter 'un­der­whelm­ing' ef­fi­ca­cy; Servi­er wins pri­or­i­ty re­view for Tib­so­vo ex­pan­sion

Clo­vis On­col­o­gy up­dat­ed in­vestors with its first quar­ter re­sults on Wednes­day morn­ing, and among its rev­e­la­tions proved some trou­bling news for a Bris­tol My­ers Squibb-part­nered pro­gram.

Pair­ing its ex­per­i­men­tal lu­ci­tanib drug with Bris­tol My­ers’ Op­di­vo in an on­go­ing Phase Ib/II study, Clo­vis re­port­ed that “un­der­whelm­ing ef­fi­ca­cy” has led them to cease de­vel­op­ment for the com­bo in non-clear-cell ovar­i­an can­cer, ex­ecs said in Wednes­day morn­ing’s earn­ings call. En­roll­ment is con­tin­u­ing in oth­er ex­pan­sion co­horts, which in­clude non-clear cell en­dome­tri­al can­cer, cer­vi­cal can­cer and clear-cell ovar­i­an and en­dome­tri­al can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.